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(citalopram, fluoxetine, paroxetine, and sertraline) and
venlafaxine in US managed care plans.
METHODS: Symmetry Health Data Systems’ Episode
Treatment Group methodology was applied to the Phar-
Metrics Integrated Outcomes Database to identify adult
subjects (18 years) diagnosed with depressive disorder
and treated with one of the study medications between
January 1, 1998 and June 30, 1999. Diagnosis codes and
prescription claims records were used to identify the
existence of comorbidities and coprescribed therapies.
Descriptive statistics were used to characterize rates of
comorbidities and coprescribing, and parametric and non-
parametric methods (ANOVA and chi-square, with correc-
tions for multiple comparisons) were used to compare rates
across medication cohorts.
RESULTS: Twelve thousand twenty six patients met the
inclusion criteria. The study cohorts were similar in terms
of demographics. Most subjects (79%) had no other
mental health diagnoses. Among those who did, anxiety
(14%) and substance abuse (6%) were most common;
paroxetine and sertraline patients had the highest rates of
these comorbidities. Hypertension (17%) and hyperlipi-
demia (12%) were the most prevalent non-mental health
comorbidities. Citalopram- and paroxetine-treated pa-
tients had the highest rates of these conditions. Coronary
artery disease was more prevalent in the paroxetine and
sertraline cohorts (p  .001) compared to other study co-
horts. Citalopram-treated patients had the highest rate of
prior psychotherapy (30%). Most subjects (90%) had no
prior use of antidepressant medications, although citalo-
pram- (11%) and venlafaxine-treated (15%) patients had
higher rates prior to index diagnosis. The most com-
monly coprescribed agents for study patients were anxi-
olytics (15%) and codeine (15%).
CONCLUSIONS: Depressed patients treated with newer
antidepressant drugs may be complex in their clinical
presentation and management. Clinicians and payers
should be aware of comorbidity and coprescribing rates
to provide optimal care for these unique populations.
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OBJECTIVE: To determine the change in schizophrenia-
related total direct medical costs following initiation of
olanzapine or risperidone therapy.
METHODS: The MEDSTAT Group’s MarketScan data-
base was used to obtain data on inpatient, outpatient,
and prescription drug claims. This database represents
the health care experiences of individuals employed in
large organizations in the US, as well as the dependants
of those individuals. Data between 1996 and 1999 were
analyzed. Patients with a diagnosis of schizophrenia, and
initiating either olanzapine or risperidone pharmacother-
apy were included in the study data set. Inpatient, outpa-
tient, and medication costs were assessed for one year
prior to, and one year following the initiation of olanzap-
ine or risperidone.
RESULTS: A total of 162 patients on olanzapine and 119
patients on risperidone were identified. There were no
significant differences between the two groups in either
patient demographics, or resource use in the year prior to
initiation of the medications. However, patients initiating
on olanzapine incurred higher total schizophrenia-related
direct medical costs in the year prior to initiation. The
mean initial dose of olanzapine was 11.5 mg, while the
mean initial dose of risperidone was 4.5 mg. For patients
initiating on olanzapine, there was no significant differ-
ence in the change in schizophrenia-related total direct
medical costs ($4,337.37 to $5,216.17; p  0.45) com-
pared to the costs in the year prior to initiation. This is
because the higher medication costs in the treatment pe-
riod were partially offset by lower inpatient costs associ-
ated with olanzapine. For patients initiating on risperi-
done, there was a statistically significant increase in
schizophrenia-related total direct medical costs ($2,751.25
to $4,995.01; p  0.04) compared to the costs in the year
prior to initiation.
CONCLUSION: The results of this study demonstrate
that while initiation of treatment for schizophrenia with
olanzapine is not associated with higher total schizophre-
nia-related direct medical costs, initiation with risperi-
done is associated with significantly higher total schizo-
phrenia-related direct medical costs over one year.
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OBJECTIVE: To assess the frequency and management
of extrapyramidal symptoms (EPS), sexual dysfunction
related adverse events (SD-RAEs) and weight changes
which may impede optimal outcomes in schizophrenic
patients under antipsychotic treatment and to perform an
economic evaluation.
METHODS: A cross-sectional study was carried-out by
61 Spanish psychiatrists (the EIRE Study Group). Outpa-
tients meeting DSM-IV criteria for schizophrenia and tak-
ing a single atypical antipsychotic (olanzapine, quetiapine
or risperidone) for at least four weeks were evaluated. EPS,
SD-RAEs and weight changes were assessed using a modi-
fied-UKU scale, which included a question for assessing
management of adverse events. Cost of antipsychotic and
